Anzeige
Meldung des Tages: Das Team hinter UberDoc! Warum Paula Muto, M.D. - und dieses Führungsteam - der eigentliche Katalysator sein könnten

Centessa Pharmaceuticals News

Aktie
WKN:  A3CQ72 ISIN:  US1523091007 US-Symbol:  CNTA Branche:  Biotechnologie Land:  Großbritannien
39,59 $
+0,01 $
+0,03%
33,565 € 14.04.26
Depot/Watchlist
Marktkapitalisierung *
-
Streubesitz
12,12%
KGV
-18,47
Index-Zuordnung
-

Centessa Pharmaceuticals News

10.04.26 - PR Newswire
Are APLS, CNTA, KZR Obtaining Fair Deals for their Shareholders?
Are APLS, CNTA, KZR Obtaining Fair Deals for their Shareholders? PR Newswire
08.04.26 - PR Newswire
SHAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--KZR, CNTA, AFBI, and APLS
SHAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--KZR, CNTA, AFBI, and APLS PR Newswire
07.04.26 - PR Newswire
Are APLS, KORE, CNTA Obtaining Fair Deals for their Shareholders?
Are APLS, KORE, CNTA Obtaining Fair Deals for their Shareholders? PR Newswire
01.04.26 - PR Newswire
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Centessa Pharmaceuticals plc (NASDAQ: CNTA)
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Centessa Pharmaceuticals plc (NASDAQ: CNTA) PR Newswire
31.03.26 - PR Newswire
Shareholder Alert: The Ademi Firm investigates whether Centessa Pharmaceuticals plc is obtaining a Fair Price for Public Shareholders
Shareholder Alert: The Ademi Firm investigates whether Centessa Pharmaceuticals plc is obtaining a Fair Price for Public Shareholders PR Newswire
31.03.26 - PR Newswire
Are APLS, CNTA, BIRD Obtaining Fair Deals for their Shareholders?
Are APLS, CNTA, BIRD Obtaining Fair Deals for their Shareholders? PR Newswire
31.03.26 - PR Newswire
Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders
Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-​wake disorders PR Newswire
14.01.26 - GlobeNewswire
Centessa Pharmaceuticals Announces Poster Presentation of New Preclinical Data Supporting Expansion of Orexin Receptor 2 (OX2R) Agonist Pipeline into Neuropsychiatric Indications at the 64th ACNP Annual Meeting
Antidepressive effects and enhanced wakefulness were observed with OX2R activation in established animal model of major depressive disorder
11.12.25 - GlobeNewswire
Centessa Pharmaceuticals Announces CEO Transition as Company Advances Strategy to Extend Orexin Leadership into Multiple Neuroscience Indications 
Mario Alberto Accardi PhD, President and founder of Centessa’s Orexin Program, appointed Chief Executive Officer and member of the Board of Directors
12.11.25 - GlobeNewswire
Centessa Pharmaceuticals Announces Pricing of $250,000,000 Public Offering of American Depositary Shares
BOSTON and LONDON, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-​stage pharmaceutical company, today announced the ...
11.11.25 - GlobeNewswire
Centessa Pharmaceuticals Announces Proposed Public Offering of American Depositary Shares
BOSTON and LONDON, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-​stage pharmaceutical company, today announced that it ...
07.11.25 - GlobeNewswire
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
BOSTON and LONDON, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-​stage pharmaceutical company that aims to discover and ...
05.11.25 - GlobeNewswire
Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2025 and Provides Update on Potential Best-in-Class Orexin Receptor 2 (OX2R) Agonist Program
ORX750: Demonstrated potential best-​in-class profile for treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH) in initial cohorts of ongoing ...
12.08.25 - GlobeNewswire
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2025
Advancing a broad, potential best-​in-class orexin receptor 2 (OX2R) agonist franchise, with key data readouts expected this year
16.06.25 - GlobeNewswire
Centessa Pharmaceuticals Announces Clearance of Investigational New Drug Application (IND) for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist; Clinical Data in Acutely Sleep-Deprived Healthy Volunteers Planned for this Year
BOSTON and LONDON, June 16, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-​stage pharmaceutical company, today announced that ...
14.05.25 - GlobeNewswire
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2025
Advancing a broad, potential best-​in-class orexin receptor 2 (OX2R) agonist franchise, with key data readouts expected this year ORX750 Phase 2a CRYSTAL-1 study for the ...

Newssuche

Videos

newspaper
07.04.26 +3,81%
Technical Trading: DAX Long kurzfristig
DAX Long Typ: Turbo Open End WKN: VJ9H40 Hebel:11,30 Laufzeit: OpenEnd Einstieg: Market ... Mehr »